InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

Core Insights - InflaRx N.V. announced positive data from a Phase 3 study of vilobelimab for pyoderma gangrenosum, presented at the 2026 AAD Annual Meeting [1][2] Group 1: Study Results - The Phase 3 trial showed higher rates of complete remission (20.8% for vilobelimab vs. 5.1% for placebo) and target ulcer closure (20.8% vs. 16.7%) [4] - Over one-third of vilobelimab-treated patients achieved more than a 50% reduction in ulcer volume (36.4% vs. 16.7% for placebo) [4] - Vilobelimab treatment significantly reduced C5a levels by -76.6% compared to -13.5% with placebo [5] Group 2: Safety Profile - The treatment was generally well tolerated, with most adverse events being mild to moderate, and similar rates of serious adverse events (6.3% for vilobelimab vs. 4.5% for placebo) [5] Group 3: Future Development - InflaRx is prioritizing discussions with the FDA regarding izicopan for hidradenitis suppurativa while also planning to explore development options for vilobelimab in pyoderma gangrenosum, likely in collaboration with a partner [6] Group 4: Product Information - Vilobelimab is a first-in-class monoclonal antibody targeting complement factor C5a, designed to block its biological activity while preserving the innate immune system's defense mechanisms [7][9]